Atlas Trials

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Clinical trial NCT05946460 · UNKNOWN

Trial details

NCT number
NCT05946460
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer
Start date
2023-08-15
Primary completion
2025-07-10
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.